SINGLE-USE AUTO-INJECTOR
    94.
    发明公开

    公开(公告)号:EP3368101A1

    公开(公告)日:2018-09-05

    申请号:EP16788129.1

    申请日:2016-10-28

    申请人: Amgen Inc.

    摘要: The present invention relates to a single-use auto-injector for injection of a dosage of a drug into a human body, comprising a housing, and a dosing unit arranged in at least part of the housing, the dosing unit comprising, a needle, a drug container comprising the drug, a piston movable in the container, a first mechanical power supply for supplying a first mechanical force for moving the piston to deliver a drug to the human body, an activation mechanism configured to release the first mechanical power of the first mechanical power supply, and a mechanical brake for controlling the movement of the piston, wherein the auto-injector comprises a second mechanical power supply for supplying a second mechanical force, the auto-injector having, a first state in which the needle is protected from needle damage or contamination, a second state in which the needle is ready to penetrate the human body for dosing the drug, a third state in which the needle has penetrated the human body and is ready to dose, and a fourth state in which the needle is shielded to avoid unintended needle sticks, wherein the second mechanical power supply is configured to shift state of the auto-injector from the third state to the fourth state by releasing the second mechanical power.

    METHOD FOR TREATING OSTEOPOROSIS
    96.
    发明授权

    公开(公告)号:EP2699261B1

    公开(公告)日:2018-07-11

    申请号:EP12717002.5

    申请日:2012-04-18

    申请人: Amgen Inc.

    IPC分类号: A61K39/395

    摘要: The invention is directed to a method for increasing bone mineral density (BMD) in a postmenopausal woman. The method comprises administering to a postmenopausal woman having a lumbar vertebrae T-score of less than or equal to −2 an anti-sclerostin antibody in an amount and for a time effective to increase lumbar vertebrae BMD at least about 9% from pretreatment baseline at twelve months following initial anti-sclerostin antibody administration. The invention also is directed to a method for treating osteoporosis. The method comprising administering to a postmenopausal woman with osteoporosis an anti-sclerostin antibody in an amount of about 70 mg to about 210 mg at once a month, optionally for about three to about 18 months. Alternatively, the method comprises administering an anti-sclerostin antibody in an amount of about 140 mg to about 210 mg every three months, optionally about six to about 18 months.